Stuart A Arbuckle Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Stuart A Arbuckle.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Stuart A Arbuckle. Stuart A Arbuckle is Director in IMMUNOGEN INC ($IMGN) and EVP, Chief Commercial Officer in VERTEX PHARMACEUTICALS INC / MA ($VRTX) and EVP\Chief Commercial Officer in VERTEX PHARMACEUTICALS INC / MA ($VRTX) and Director in Cerulean Pharma Inc. ($CERU) and Director in RHYTHM PHARMACEUTICALS, INC. ($RYTM).
Latest Insider Trading Transactions of Stuart A Arbuckle
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, DARE, IMGN, RYTM, VRTX
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Feb 26 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 216.57 | 254 | 55,009 | 41,103 | 41.4 K to 41.1 K (-0.61 %) |
Feb 26 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 215.62 | 300 | 64,686 | 41,357 | 41.7 K to 41.4 K (-0.72 %) |
Feb 26 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 214.32 | 400 | 85,728 | 41,657 | 42.1 K to 41.7 K (-0.95 %) |
Feb 26 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 213.55 | 1,400 | 298,970 | 42,057 | 43.5 K to 42.1 K (-3.22 %) |
Feb 26 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 212.52 | 900 | 191,268 | 43,457 | 44.4 K to 43.5 K (-2.03 %) |
Feb 26 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 211.39 | 380 | 80,328 | 44,357 | 44.7 K to 44.4 K (-0.85 %) |
Feb 26 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Payment of Exercise | F | 217.57 | 2,898 | 630,518 | 44,737 | 47.6 K to 44.7 K (-6.08 %) |
Feb 19 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 213.26 | 100 | 21,326 | 47,635 | 47.7 K to 47.6 K (-0.21 %) |
Feb 19 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 212.49 | 2,763 | 587,110 | 47,735 | 50.5 K to 47.7 K (-5.47 %) |
Feb 19 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 211.77 | 3,940 | 834,374 | 50,498 | 54.4 K to 50.5 K (-7.24 %) |
Feb 19 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 210.05 | 1,022 | 214,671 | 54,438 | 55.5 K to 54.4 K (-1.84 %) |
Feb 19 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Payment of Exercise | F | 211.75 | 6,240 | 1,321,320 | 55,460 | 61.7 K to 55.5 K (-10.11 %) |
Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Option Exercise | M | 86.52 | 1,554 | 134,452 | 0 | |
Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 216.83 | 89 | 19,298 | 69,957 | 70 K to 70 K (-0.13 %) |
Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 215.80 | 90 | 19,422 | 70,046 | 70.1 K to 70 K (-0.13 %) |
Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 214.98 | 242 | 52,025 | 70,136 | 70.4 K to 70.1 K (-0.34 %) |
Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 213.90 | 497 | 106,308 | 70,378 | 70.9 K to 70.4 K (-0.70 %) |
Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 212.77 | 488 | 103,832 | 70,875 | 71.4 K to 70.9 K (-0.68 %) |
Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 211.22 | 148 | 31,261 | 71,363 | 71.5 K to 71.4 K (-0.21 %) |
Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Buy | M | 86.52 | 1,554 | 134,452 | 71,511 | 70 K to 71.5 K (+2.22 %) |
Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Grant | A | 0.00 | 13,952 | 0 | 69,957 | 56 K to 70 K (+24.91 %) |
Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Grant | A | 0.00 | 12,388 | 0 | 56,005 | 43.6 K to 56 K (+28.40 %) |
Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Option Exercise | M | 86.52 | 1,554 | 134,452 | 0 | |
Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Grant | A | 0.00 | 8,438 | 0 | 43,617 | 35.2 K to 43.6 K (+23.99 %) |
Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 216.83 | 89 | 19,298 | 69,957 | 70 K to 70 K (-0.13 %) |
Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 215.80 | 90 | 19,422 | 70,046 | 70.1 K to 70 K (-0.13 %) |
Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 214.98 | 242 | 52,025 | 70,136 | 70.4 K to 70.1 K (-0.34 %) |
Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 213.90 | 497 | 106,308 | 70,378 | 70.9 K to 70.4 K (-0.70 %) |
Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 212.77 | 488 | 103,832 | 70,875 | 71.4 K to 70.9 K (-0.68 %) |
Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 211.22 | 148 | 31,261 | 71,363 | 71.5 K to 71.4 K (-0.21 %) |
Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Buy | M | 86.52 | 1,554 | 134,452 | 71,511 | 70 K to 71.5 K (+2.22 %) |
Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Grant | A | 0.00 | 13,952 | 0 | 69,957 | 56 K to 70 K (+24.91 %) |
Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Grant | A | 0.00 | 12,388 | 0 | 56,005 | 43.6 K to 56 K (+28.40 %) |
Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Grant | A | 0.00 | 8,438 | 0 | 43,617 | 35.2 K to 43.6 K (+23.99 %) |
Nov 18 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 224.11 | 5 | 1,121 | 35,179 | 35.2 K to 35.2 K (-0.01 %) |
Nov 18 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 222.47 | 2 | 445 | 35,184 | 35.2 K to 35.2 K (-0.01 %) |
Nov 05 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Option Exercise | M | 86.52 | 1,553 | 134,366 | 1,554 | |
Nov 05 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 214.13 | 334 | 71,519 | 35,179 | 35.5 K to 35.2 K (-0.94 %) |
Nov 05 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 212.38 | 245 | 52,033 | 35,513 | 35.8 K to 35.5 K (-0.69 %) |
Nov 05 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 211.54 | 487 | 103,020 | 35,758 | 36.2 K to 35.8 K (-1.34 %) |
Nov 05 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 210.56 | 487 | 102,543 | 36,245 | 36.7 K to 36.2 K (-1.33 %) |
Nov 05 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Buy | M | 86.52 | 1,553 | 134,366 | 36,732 | 35.2 K to 36.7 K (+4.41 %) |
Aug 05 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Option Exercise | M | 86.52 | 1,553 | 134,366 | 3,107 | |
Aug 05 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 279.58 | 280 | 78,282 | 35,179 | 35.5 K to 35.2 K (-0.79 %) |
Aug 05 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 278.72 | 689 | 192,038 | 35,459 | 36.1 K to 35.5 K (-1.91 %) |
Aug 05 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 277.85 | 413 | 114,752 | 36,148 | 36.6 K to 36.1 K (-1.13 %) |
Aug 05 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 276.40 | 171 | 47,264 | 36,561 | 36.7 K to 36.6 K (-0.47 %) |
Aug 05 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Buy | M | 86.52 | 1,553 | 134,366 | 36,732 | 35.2 K to 36.7 K (+4.41 %) |
Jul 09 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Option Exercise | M | 155.57 | 1,222 | 190,107 | 8,561 | |
Jul 09 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Option Exercise | M | 187.53 | 1,564 | 293,297 | 17,206 | |
Jul 09 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 300.00 | 2,786 | 835,800 | 35,179 | 38 K to 35.2 K (-7.34 %) |
Jul 09 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Buy | M | 155.57 | 1,222 | 190,107 | 37,965 | 36.7 K to 38 K (+3.33 %) |
Jul 09 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Buy | M | 187.53 | 1,564 | 293,297 | 36,743 | 35.2 K to 36.7 K (+4.45 %) |
Jun 18 2020 | RYTM | RHYTHM PHARMACEUTI ... | Arbuckle Stuart A | Director | Option Exercise | A | 21.37 | 18,500 | 395,345 | 18,500 | |
Jun 18 2020 | IMGN | ImmunoGen, Inc. | Arbuckle Stuart A | Director | Option Exercise | A | 4.56 | 50,000 | 228,000 | 50,000 | |
Jun 18 2020 | IMGN | ImmunoGen, Inc. | Arbuckle Stuart A | Director | Option Exercise | A | 0.00 | 17,000 | 0 | 33,000 | |
May 19 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 288.35 | 9 | 2,595 | 35,179 | 35.2 K to 35.2 K (-0.03 %) |
May 19 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 287.62 | 24 | 6,903 | 35,188 | 35.2 K to 35.2 K (-0.07 %) |
May 19 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 286.41 | 21 | 6,015 | 35,212 | 35.2 K to 35.2 K (-0.06 %) |
May 19 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 285.00 | 10 | 2,850 | 35,233 | 35.2 K to 35.2 K (-0.03 %) |
May 19 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 283.58 | 10 | 2,836 | 35,243 | 35.3 K to 35.2 K (-0.03 %) |
May 19 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 280.71 | 12 | 3,369 | 35,253 | 35.3 K to 35.3 K (-0.03 %) |
May 19 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 279.93 | 17 | 4,759 | 35,265 | 35.3 K to 35.3 K (-0.05 %) |
May 19 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 276.35 | 10 | 2,764 | 35,282 | 35.3 K to 35.3 K (-0.03 %) |
May 06 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Option Exercise | M | 86.52 | 1,553 | 134,366 | 4,660 | |
May 06 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 264.89 | 113 | 29,933 | 35,179 | 35.3 K to 35.2 K (-0.32 %) |
May 06 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 262.54 | 240 | 63,010 | 35,292 | 35.5 K to 35.3 K (-0.68 %) |
May 06 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 261.34 | 240 | 62,722 | 35,532 | 35.8 K to 35.5 K (-0.67 %) |
May 06 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 260.32 | 320 | 83,302 | 35,772 | 36.1 K to 35.8 K (-0.89 %) |
May 06 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 259.36 | 640 | 165,990 | 36,092 | 36.7 K to 36.1 K (-1.74 %) |
May 06 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Buy | M | 86.52 | 1,553 | 134,366 | 36,732 | 35.2 K to 36.7 K (+4.41 %) |
Feb 26 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 238.33 | 632 | 150,625 | 35,179 | 35.8 K to 35.2 K (-1.76 %) |
Feb 26 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 236.88 | 20 | 4,738 | 35,811 | 35.8 K to 35.8 K (-0.06 %) |
Feb 26 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 236.36 | 420 | 99,271 | 35,831 | 36.3 K to 35.8 K (-1.16 %) |
Feb 26 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 235.14 | 540 | 126,976 | 36,251 | 36.8 K to 36.3 K (-1.47 %) |
Feb 26 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 234.08 | 420 | 98,314 | 36,791 | 37.2 K to 36.8 K (-1.13 %) |
Feb 26 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 232.35 | 360 | 83,646 | 37,211 | 37.6 K to 37.2 K (-0.96 %) |
Feb 26 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 230.85 | 432 | 99,727 | 37,571 | 38 K to 37.6 K (-1.14 %) |
Feb 26 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 229.78 | 810 | 186,122 | 38,003 | 38.8 K to 38 K (-2.09 %) |
Feb 26 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Payment of Exercise | F | 239.23 | 2,898 | 693,289 | 38,813 | 41.7 K to 38.8 K (-6.95 %) |
Feb 19 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 245.76 | 377 | 92,652 | 41,711 | 42.1 K to 41.7 K (-0.90 %) |
Feb 19 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 245.04 | 580 | 142,123 | 42,088 | 42.7 K to 42.1 K (-1.36 %) |
Feb 19 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 243.76 | 400 | 97,504 | 42,668 | 43.1 K to 42.7 K (-0.93 %) |
Feb 19 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 242.91 | 1,011 | 245,582 | 43,068 | 44.1 K to 43.1 K (-2.29 %) |
Feb 19 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 242.08 | 760 | 183,981 | 44,079 | 44.8 K to 44.1 K (-1.69 %) |
Feb 19 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Payment of Exercise | F | 241.50 | 2,496 | 602,784 | 44,839 | 47.3 K to 44.8 K (-5.27 %) |
Feb 12 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 248.62 | 486 | 120,829 | 47,335 | 47.8 K to 47.3 K (-1.02 %) |
Feb 12 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 247.91 | 1,863 | 461,856 | 47,821 | 49.7 K to 47.8 K (-3.75 %) |
Feb 12 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 246.76 | 1,770 | 436,765 | 49,684 | 51.5 K to 49.7 K (-3.44 %) |
Feb 12 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 245.93 | 3,377 | 830,506 | 51,454 | 54.8 K to 51.5 K (-6.16 %) |
Feb 12 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 244.99 | 2,860 | 700,671 | 54,831 | 57.7 K to 54.8 K (-4.96 %) |
Feb 12 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 243.76 | 930 | 226,697 | 57,691 | 58.6 K to 57.7 K (-1.59 %) |
Feb 12 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Payment of Exercise | F | 240.95 | 8,942 | 2,154,575 | 58,621 | 67.6 K to 58.6 K (-13.24 %) |
Feb 07 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Option Exercise | M | 155.57 | 1,223 | 190,262 | 9,783 | |
Feb 07 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Option Exercise | M | 187.53 | 1,564 | 293,297 | 18,770 | |
Feb 07 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 242.47 | 171 | 41,462 | 67,563 | 67.7 K to 67.6 K (-0.25 %) |
Feb 07 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 241.08 | 150 | 36,162 | 67,734 | 67.9 K to 67.7 K (-0.22 %) |
Feb 07 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 240.53 | 230 | 55,322 | 67,884 | 68.1 K to 67.9 K (-0.34 %) |
Feb 07 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 239.47 | 725 | 173,616 | 68,114 | 68.8 K to 68.1 K (-1.05 %) |
Feb 07 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 238.71 | 1,511 | 360,691 | 68,839 | 70.4 K to 68.8 K (-2.15 %) |
Feb 07 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Buy | M | 155.57 | 1,223 | 190,262 | 70,350 | 69.1 K to 70.4 K (+1.77 %) |
Feb 07 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Buy | M | 187.53 | 1,564 | 293,297 | 69,127 | 67.6 K to 69.1 K (+2.31 %) |
Feb 07 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Grant | A | 0.00 | 12,387 | 0 | 67,563 | 55.2 K to 67.6 K (+22.45 %) |
Feb 07 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Grant | A | 0.00 | 9,800 | 0 | 55,176 | 45.4 K to 55.2 K (+21.60 %) |
Feb 07 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Grant | A | 0.00 | 12,136 | 0 | 45,376 | 33.2 K to 45.4 K (+36.51 %) |
Feb 04 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Option Exercise | M | 86.52 | 1,554 | 134,452 | 6,213 | |
Feb 04 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Option Exercise | M | 91.05 | 2,156 | 196,304 | 0 | |
Feb 04 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Option Exercise | M | 187.53 | 4,692 | 879,891 | 20,334 | |
Feb 04 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 232.71 | 540 | 125,663 | 33,240 | 33.8 K to 33.2 K (-1.60 %) |
Feb 04 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 231.87 | 900 | 208,683 | 33,780 | 34.7 K to 33.8 K (-2.60 %) |
Feb 04 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 231.16 | 1,300 | 300,508 | 34,680 | 36 K to 34.7 K (-3.61 %) |
Feb 04 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 229.99 | 530 | 121,895 | 35,980 | 36.5 K to 36 K (-1.45 %) |
Feb 04 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 228.90 | 440 | 100,716 | 36,510 | 37 K to 36.5 K (-1.19 %) |
Feb 04 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | M | 86.52 | 1,554 | 134,452 | 36,950 | 38.5 K to 37 K (-4.04 %) |
Feb 04 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | M | 91.05 | 2,156 | 196,304 | 35,396 | 37.6 K to 35.4 K (-5.74 %) |
Feb 04 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 238.65 | 4,692 | 1,119,746 | 33,240 | 37.9 K to 33.2 K (-12.37 %) |
Feb 04 2020 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Buy | M | 187.53 | 4,692 | 879,891 | 37,932 | 33.2 K to 37.9 K (+14.12 %) |
Nov 15 2019 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Option Exercise | M | 155.57 | 8,560 | 1,331,679 | 11,006 | |
Nov 15 2019 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Sell | S | 205.57 | 8,560 | 1,759,679 | 33,240 | 41.8 K to 33.2 K (-20.48 %) |
Nov 15 2019 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Buy | M | 155.57 | 8,560 | 1,331,679 | 41,800 | 33.2 K to 41.8 K (+25.75 %) |
Nov 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Option Exercise | M | 86.52 | 1,553 | 134,366 | 7,767 | |
Nov 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Option Exercise | M | 91.05 | 2,155 | 196,213 | 2,156 | |
Nov 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Sell | S | 201.62 | 1,553 | 313,116 | 33,240 | 34.8 K to 33.2 K (-4.46 %) |
Nov 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Buy | M | 86.52 | 1,553 | 134,366 | 34,793 | 33.2 K to 34.8 K (+4.67 %) |
Nov 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Sell | S | 201.62 | 2,155 | 434,491 | 33,240 | 35.4 K to 33.2 K (-6.09 %) |
Nov 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Buy | M | 91.05 | 2,155 | 196,213 | 35,395 | 33.2 K to 35.4 K (+6.48 %) |
Aug 12 2019 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Option Exercise | M | 131.89 | 2,125 | 280,266 | 0 | |
Aug 12 2019 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Sell | S | 181.89 | 2,125 | 386,516 | 33,240 | 35.4 K to 33.2 K (-6.01 %) |
Aug 12 2019 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Buy | M | 131.89 | 2,125 | 280,266 | 35,365 | 33.2 K to 35.4 K (+6.39 %) |
Aug 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Option Exercise | M | 86.52 | 1,553 | 134,366 | 9,320 | |
Aug 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Option Exercise | M | 91.05 | 2,155 | 196,213 | 4,311 | |
Aug 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Sell | S | 176.44 | 1,553 | 274,011 | 32,240 | 33.8 K to 32.2 K (-4.60 %) |
Aug 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Buy | M | 86.52 | 1,553 | 134,366 | 33,793 | 32.2 K to 33.8 K (+4.82 %) |
Aug 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Sell | S | 177.78 | 2,155 | 383,116 | 32,240 | 34.4 K to 32.2 K (-6.27 %) |
Aug 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Buy | M | 91.05 | 2,155 | 196,213 | 34,395 | 32.2 K to 34.4 K (+6.68 %) |
Aug 01 2019 | RYTM | RHYTHM PHARMACEUTI ... | Arbuckle Stuart A | Director | Option Exercise | A | 19.05 | 30,000 | 571,500 | 30,000 | |
Jun 24 2019 | IMGN | IMMUNOGEN INC | Arbuckle Stuart A | Director | Option Exercise | A | 2.10 | 18,000 | 37,800 | 18,000 | |
Jun 24 2019 | IMGN | IMMUNOGEN INC | Arbuckle Stuart A | Director | Option Exercise | A | 0.00 | 4,000 | 0 | 16,000 | |
Jun 20 2019 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Option Exercise | M | 131.89 | 2,125 | 280,266 | 2,125 | |
Jun 20 2019 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Sell | S | 181.89 | 2,125 | 386,516 | 33,240 | 35.4 K to 33.2 K (-6.01 %) |
Jun 20 2019 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Buy | M | 131.89 | 2,125 | 280,266 | 35,365 | 33.2 K to 35.4 K (+6.39 %) |
May 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Option Exercise | M | 86.52 | 1,553 | 134,366 | 10,873 | |
May 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Option Exercise | M | 91.05 | 2,155 | 196,213 | 6,466 | |
May 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Sell | S | 173.60 | 593 | 102,945 | 33,240 | 33.8 K to 33.2 K (-1.75 %) |
May 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Sell | S | 172.73 | 400 | 69,092 | 33,833 | 34.2 K to 33.8 K (-1.17 %) |
May 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Sell | S | 171.31 | 320 | 54,819 | 34,233 | 34.6 K to 34.2 K (-0.93 %) |
May 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Sell | S | 170.28 | 240 | 40,867 | 34,553 | 34.8 K to 34.6 K (-0.69 %) |
May 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Buy | M | 86.52 | 1,553 | 134,366 | 34,793 | 33.2 K to 34.8 K (+4.67 %) |
May 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Sell | S | 171.70 | 100 | 17,170 | 33,240 | 33.3 K to 33.2 K (-0.30 %) |
May 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Sell | S | 170.72 | 400 | 68,288 | 33,340 | 33.7 K to 33.3 K (-1.19 %) |